- Home
- SCNX vs MBRX Comparison
SCNX vs MBRX Comparison
Compare SCNX & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- MBRX
- Stock Information
- Founded
- SCNX 2010
- MBRX 2015
- Country
- SCNX United States
- MBRX United States
- Employees
- SCNX N/A
- MBRX N/A
- Industry
- SCNX Other Pharmaceuticals
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- MBRX Health Care
- Exchange
- SCNX Nasdaq
- MBRX Nasdaq
- Market Cap
- SCNX 14.4M
- MBRX 12.9M
- IPO Year
- SCNX 2020
- MBRX 2016
- Fundamental
- Price
- SCNX $0.96
- MBRX $0.31
- Analyst Decision
- SCNX
- MBRX Strong Buy
- Analyst Count
- SCNX 0
- MBRX 3
- Target Price
- SCNX N/A
- MBRX $5.33
- AVG Volume (30 Days)
- SCNX 125.4K
- MBRX 5.2M
- Earning Date
- SCNX 08-10-2025
- MBRX 08-13-2025
- Dividend Yield
- SCNX N/A
- MBRX N/A
- EPS Growth
- SCNX N/A
- MBRX N/A
- EPS
- SCNX N/A
- MBRX N/A
- Revenue
- SCNX $146,901.00
- MBRX N/A
- Revenue This Year
- SCNX N/A
- MBRX N/A
- Revenue Next Year
- SCNX N/A
- MBRX N/A
- P/E Ratio
- SCNX N/A
- MBRX N/A
- Revenue Growth
- SCNX N/A
- MBRX N/A
- 52 Week Low
- SCNX $0.69
- MBRX $0.25
- 52 Week High
- SCNX $23.77
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- MBRX 24.39
- Support Level
- SCNX N/A
- MBRX $0.25
- Resistance Level
- SCNX N/A
- MBRX $0.42
- Average True Range (ATR)
- SCNX 0.00
- MBRX 0.06
- MACD
- SCNX 0.00
- MBRX -0.03
- Stochastic Oscillator
- SCNX 0.00
- MBRX 13.07
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.